Articles From: ESB Financial Corporation Announces Cash Dividend to Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results


2014/9/16
ESB Financial Corporation announced that at its Board of Directors meeting today, September 16, 2014, declared a quarterly cash dividend of $0.10 on the Common Stock of ESB Financial Corporation payable on October 24, 2014 to the stockholders of record at the close of business on September 30, 2014.
Sign-up for ESB Financial Corporation Announces Cash Dividend investment picks
ESB Financial Corporation (Nasdaq: ESBF), the parent company of ESB Bank, today announced earnings for the quarter ended September 30, 2014 of $0.26 per diluted share on net income of $4.6 million compared to earnings of $0.23 per diluted share on net income of $4.0 million for the quarter ended September 30, 2013, a 13.0% increase in net income per diluted share.
Sign-up for ESB Financial Corporation Announces Increased Third Quarter Earnings investment picks
2014/11/5
WILMINGTON, Del.
Sign-up for ESB FINANCIAL CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout investment picks
2014/10/31
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of ESB Financial Corp.
Sign-up for ESB FINANCIAL SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to WesBanco investment picks
2014/10/16
FLINT, Mich.
Sign-up for Esbriet® (pirfenidone) receives FDA approval under 'breakthrough status'; Diplomat to distribute investment picks
EVANSVILLE, Ind.
Sign-up for Escalade Acquires Cue And Case Sales, Inc.® investment picks
DENVER and HOUSTON , Sept.
Sign-up for Escalera Resources Announces Closing of $250 Million Credit Facility investment picks
DENVER and HOUSTON , Aug.
Sign-up for Escalera Resources Reports Second Quarter Financial and Operating Results investment picks
Receives Authorization to Apply the CE Mark to the Sonomed Escalon VuPad™ ARDMORE, Pa.
Sign-up for Escalon® Medical Corp. Reports Fiscal 2014 Results investment picks
Diodes Incorporated (Nasdaq: DIOD), a leading global manufacturer and supplier of high-quality application specific standard products within the broad discrete, logic and analog semiconductor markets, today introduces an automotive-quality graded ESD and surge protector offering improved protection, greater reliability and easier inspection during manufacturing compared to Zener-based and varistor devices.
Sign-up for ESD and Surge Protector from Diodes Incorporated Offers Optimal Protection and Easy Inspection investment picks
ESH Hospitality, Inc., which along with Extended Stay America, Inc. (NYSE:STAY) (together, the “Company”) is an issuer of the Company’s Paired Shares, today announced that Lisa Palmer has been appointed to its Board of Directors as an independent director.
Sign-up for ESH Hospitality, Inc. Announces Appointment of Lisa Palmer to Board of Directors investment picks
Electro Scientific Industries, Inc. (NASDAQ:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced that Richard H.
Sign-up for ESI Adds New Board Member investment picks
Electro Scientific Industries, Inc. (NASDAQ:ESIO), an innovator of laser-based manufacturing solutions for the microtechnology industry, today announced the µFlex TM Series multi-axis precision laser micromachining platform, enabling new levels of price-performance in laser applications for consumer electronics, medical devices, automotive components, and many other industries.
Sign-up for ESI Announces New Highly Versatile Laser Micromachining Platform investment picks
Electro Scientific Industries, Inc. (NASDAQ:ESIO), the premier source for innovative laser-based manufacturing solutions for the microtechnology industry, today announced results for its fiscal 2015 second quarter ended September 27, 2014.
Sign-up for ESI Announces Second Quarter Fiscal 2015 Results investment picks
Electro Scientific Industries, Inc. (Nasdaq:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced that its board of directors declared a quarterly cash dividend of $0.08 per share.
Sign-up for ESI Declares Quarterly Dividend investment picks
Electro Scientific Industries, Inc. (Nasdaq: ESIO), the premier source for innovative laser-based manufacturing solutions for the microtechnology industry, will announce results for its fiscal 2015 second quarter after the market closes on Thursday, October 30, 2014.
Sign-up for ESI Schedules Fiscal 2015 Second Quarter Earnings Conference Call for October 30 investment picks
Schubert Jonckheer & Kolbe LLP Investigates Case Against the Company's Top Executives SAN FRANCISCO , Sep.
Sign-up for ESI Shareholder Alert: Do You Own Stock in ITT Educational Services? investment picks
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, will host its 2014 Investor and Financial Analyst Conference in New York on October 1.
Sign-up for ESI to Host Investor and Analyst Conference in New York on October 1 investment picks
Today Esio Water & Beverage Development Corp.
Sign-up for Esio Water & Beverage Development Corp. Announced Execution of Letter of Intent to Acquire iMetabolic, Inc. investment picks
WHIPPANY, N.J. , Sept.
Sign-up for ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of Esperion Therapeutics Inc. rallied after the drug developer said its treatment significantly lowered bad cholesterol in patients enrolled in a clinical trial.
Sign-up for Esperion shares rally on cholesterol drug study investment picks
Esperion Therapeutics Inc. (ESPR) shares rallied in the extended session Wednesday after the drug developer said a mid-stage clinical trial showed its drug candidate significantly lowered bad cholesterol.
Sign-up for Esperion shares rally on cholesterol drug study results investment picks
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the closing of its follow-on public offering of 4,887,500 shares of common stock, offered at a price to the public of $20.00 per share, which includes the exercise in full by the underwriters of their option to purchase 637,500 additional shares of common stock.
Sign-up for Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock investment picks
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-008, a Phase 2b study evaluating the efficacy and safety of ETC-1002 monotherapy compared with ezetimibe monotherapy in patients with hypercholesterolemia, with or without statin intolerance.
Sign-up for Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia investment picks
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that it intends to offer and sell, subject to market and other conditions, $85 million of its common stock in an underwritten public offering.
Sign-up for Esperion Therapeutics Announces Proposed Public Offering of Common Stock investment picks
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the third quarter ended September 30, 2014.
Sign-up for Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: ESB Financial Corporation Announces Cash Dividend to Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent